Find out more about Allergan’s presbyopia drop NDA filing

March 4, 2021
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director

,
Michael Robinson, MD

Potential presbyopia treatment coming

Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.

Click here to read this interview's transcript

Click here to listen to this interview's podcast